
Advances in Cancer Research
Description
Key Features
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Readership
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
Table of Contents
1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patients
Jayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza
2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations
Ryan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran
3. The second genome: Effects of the mitochondrial genome on cancer progression
Adam D. Scheid, Thomas C. Beadnell and Danny R. Welch
4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors
Manny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro
5. HVEM network signaling in cancer
John R. Šedý and Parham Ramezani-Rad
6. Pharmacology of ME-344, a novel cytotoxic isoflavone
Leilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew
Product details
- No. of pages: 217
- Language: English
- Copyright: © Academic Press 2019
- Published: March 15, 2019
- Imprint: Academic Press
- Hardcover ISBN: 9780128171530
- eBook ISBN: 9780128171547
About the Serial Volume Editors
Paul Fisher

Affiliations and Expertise
Kenneth Tew

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.